Skip to content
ClinCalc Pro
Menu
Fifth-generation cephalosporin (anti-MRSA)

Ceftaroline fosamil

Brand names: Zinforo

Ceftaroline fosamil is a parenteral cephalosporin antibacterial notable for activity against meticillin-resistant Staphylococcus aureus (MRSA), used for complicated skin and soft-tissue infections and community-acquired pneumonia.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Its active form is a beta-lactam that binds penicillin-binding proteins, including PBP2a in MRSA, to inhibit cell-wall synthesis and produce a bactericidal effect.

Prescribing in practice

  • Avoid in patients with a history of immediate hypersensitivity to penicillins or other beta-lactams because of the risk of cross-reactivity.
  • Its anti-MRSA activity is a key distinguishing feature, but use should be guided by susceptibility data and antimicrobial stewardship.
  • Dose adjustment is required in renal impairment, in line with the SPC.

Monitoring

Monitor renal function, clinical response and full blood count, with awareness of direct antiglobulin (Coombs) test seroconversion during therapy.

Counselling the patient

  • This antibiotic is given by infusion under clinical supervision.
  • Report any rash, swelling, breathing difficulty, or severe or persistent diarrhoea.

Evidence & guidelines

Efficacy in complicated skin infection and community-acquired pneumonia was established in the CANVAS and FOCUS phase III trial programmes.

Reference: BSAC; UKHSA AMR; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.